Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis danger: a new model aims to predict sudden blood pressure crashes

NCT ID NCT03350308

Knowledge-focused Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study is testing whether measuring residual blood volume and excess fluid during hemodialysis can predict the risk of intradialytic hypotension—a sudden drop in blood pressure that can cause dizziness, nausea, or fainting. Researchers will follow 60 adults with chronic kidney disease who have experienced at least two such episodes in the past month. The goal is to build a statistical model that could help dialysis teams anticipate and prevent these dangerous events.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hemodialysis
What this could lead to
If successful, this could lead to a predictive tool that helps dialysis teams anticipate and prevent dangerous blood pressure drops during treatment.
What could go wrong
This is a small, early-stage study focused on building a prediction model, not a treatment. The model may not be accurate enough for broader use, and individual patient factors could limit its reliability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Jan 2015

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with chronic end-stage renal failure

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years old minimum patients * Patients with chronic end-stage renal failure * Patients treated with hemodialysis for at least 3 months, 3 times a week (duration of sessions 3 to 5 hours) * Patients with at least 2 episodes of intradialytic hypotension in the last month * Patients without acute events within 3 months prior to inclusion * Patients affiliated with or receiving social security benefits Exclusion Criteria: * Hemoglobin levels outside the limits of measurement (\<7 g/L or \>15g/L) * Patients whose probable survival does not exceed 6 months * Patients with progressive acute pathology * Patient following another research protocol that may influence results * Patients with psychiatric pathology or cognitive impairments that make them unable to give informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronical kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease hypotensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronical kidney disease Hemodialysis Hypotension Residual blood volume

Contacts and locations

Locations

  • CHU Clermont-Ferrand

    Clermont-Ferrand, 63003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.